一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
肿瘤细胞治疗研究
英文原题:Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.
Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
天然4-1BBL(CD137L)是一种细胞膜结合蛋白,对CD8+ T细胞的扩增、效应功能和存活至关重要。我们曾报道了一种具有活性的可溶性寡聚体构建体SA-4-1BBL的生成,并在多种小鼠肿瘤模型中证明了其免疫预防和免疫治疗疗效。
在此,我们开发了一种溶瘤腺病毒(OAd),用于将SA-4-1BBL(OAdSA-4-1BBL)递送并表达于实体瘤中以进行免疫治疗。该构建体表达的SA-4-1BBL蛋白在体外可促进T细胞增殖。OAdSA-4-1BBL降低了两种小鼠肺癌细胞系TC-1和CMT64的细胞活力,但未降低非癌性肺MM14.Lu细胞系的细胞活力。OAdSA-4-1BBL诱导了I型和II型程序性细胞死亡(分别为凋亡和自噬),并且还检测到自噬介导的三磷酸腺苷(ATP)释放。瘤内注射OAdSA-4-1BBL可在肿瘤中有效表达SA-4-1BBL蛋白,从而在同基因皮下TC-1小鼠肺癌模型中产生显著的肿瘤抑制。肿瘤抑制与树突状细胞频率升高以及细胞毒性CD8+ T细胞和NK细胞向肿瘤的浸润增加相关。
我们的数据表明,OAdSA-4-1BBL作为一种单独构建体或与其他免疫治疗方式(如免疫检查点抑制剂)联合使用,可能为肺癌提供一种有效的替代治疗策略。
Natural 4-1BBL (CD137L) is a cell membrane-bound protein critical to the expansion, effector function, and survival of CD8 + T cells.
We reported the generation of an active soluble oligomeric construct, SA-4-1BBL, with demonstrated immunoprevention and immunotherapeutic efficacy in various mouse tumor models.
Herein, we developed an oncolytic adenovirus (OAd) for the delivery and expression of SA-4-1BBL (OAdSA-4-1BBL) into solid tumors for immunotherapy. SA-4-1BBL protein expressed by this construct produced T-cell proliferation in vitro. OAdSA-4-1BBL decreased cell viability in two mouse lung cancer cell lines, TC-1 and CMT64, but not in the non-cancerous lung MM14. Lu cell line.
OAdSA-4-1BBL induced programmed cell death types I and II (apoptosis and autophagy, respectively), and autophagy-mediated adenosine triphosphate (ATP) release was also detected. Intratumoral injection of OAdSA-4-1BBL efficiently expressed the SA-4-1BBL protein in the tumors, resulting in significant tumor suppression in a syngeneic subcutaneous TC-1 mouse lung cancer model. Tumor suppression was associated with a higher frequency of dendritic cells and an increased infiltration of cytotoxic CD8 + T and NK cells into the tumors.
Our data suggest that OAdSA-4-1BBL may present an efficacious alternative therapeutic strategy against lung cancer as a standalone construct or in combination with other immunotherapeutic modalities, such as immune checkpoint inhibitors.
MEMBER ACCOUNT
登录成功会直接打开下一页。